All In Biotech

Drug Trial Radar · NCT02006472

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45, 67.5, 90, and 112.5 mg Twice-Daily vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

Last checked: Nov 19, 2026Latest source record: Jul 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 408 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

408

Actual

Start

Feb 28, 2014

Primary completion

Dec 16, 2015

Study completion Jul 7, 2016

Sponsor

Lead sponsor
PrileniaIndustry
Sponsor type
Industry
Collaborators
European Huntington's Disease Network; Huntington Study Group
First posted
Dec 10, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, multinational, randomized, parallel-group, double-blind, placebo-controlled, dose range finding study to compare the efficacy and safety of different doses of pridopidine versus placebo in the treatment of motor impairment in Huntington's Disease (HD).

Conditions

  • Huntington's Disease

Interventions

  • PridopidineDrug

    22.5 mg and 45 mg capsules

  • PlaceboOther

    Capsules matching drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26Time frame: 26 weeks

Locations

58 sites in 12 countries. Site status is shown where the registry gives one.

  • Investigational Site 12199

    La Jolla, California

  • Investigational Site 12204

    Los Angeles, California

  • Investigational Site 12201

    Englewood, Colorado

  • Investigational Site 12196

    Washington D.C., District of Columbia

  • Investigational Site 12207

    Chicago, Illinois

  • Investigational Site 12202

    Baltimore, Maryland

  • Investigational Site 12206

    Baltimore, Maryland

  • Investigational Site 12200

    Manhasset, New York

  • Investigational Site 12203

    New York, New York

  • Investigational Site 12198

    Rochester, New York

  • Investigational Site 12211

    Winston-Salem, North Carolina

  • Investigational Site 12205

    Cincinnati, Ohio

  • Investigational Site 12209

    Pittsburgh, Pennsylvania

  • Investigational Site 12208

    Salt Lake City, Utah

  • Investigational Site 12210

    Richmond, Virginia

  • Investigational Site 12197

    Kirkland, Washington

  • Investigational Site 78055

    Caulfield South, Australia

  • Investigational Site 78056

    Kew, Australia

  • Investigational Site 78058

    Subiaco, Australia

  • Investigational Site 78057

    Westmead, Australia

  • Investigational Site 33021

    Innsbruck, Austria

  • Investigational Site 33027

    Vienna, Austria

  • Investigational Site 11035

    Vancouver, British Columbia, Canada

  • Investigational Site 11037

    Ottawa, Ontario, Canada

  • Investigational Site 11036

    Toronto, Ontario, Canada

  • Investigational Site 39028

    Aarhus, Denmark

  • Investigational Site 39027

    Copenhagen, Denmark

  • Investigational Site 35123

    Angers, France

  • Investigational Site 35122

    Créteil, France

  • Investigational Site 35125

    Lille, France

  • Investigational Site 35124

    Marseille, France

  • Investigational Site 35121

    Salouël, France

  • Investigational Site 35165

    Toulouse, France

  • Investigational Site 32408

    Berlin, Germany

  • Investigational Site 32410

    Bochum, Germany

  • Investigational Site 32409

    Münster, Germany

  • Investigational Site 32407

    Ulm, Germany

  • Investigational Site 30083

    Florence, Italy

  • Investigational Site 30080

    Milan, Italy

  • Investigational Site 30082

    Naples, Italy

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.